Cymabay Therapeu

Company Profile

Cymabay Therapeu had its IPO on 2014-02-03 under the ticker symbol CBAY.

The company operates in the Healthcare sector and Biotechnology industry. Cymabay Therapeu has a staff strength of 0 employees.

Stock update

Shares of Cymabay Therapeu opened at $8.85 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $8.45 - $8.95, and closed at $8.47.

This is a -5.36% slip from the previous day's closing price.

A total volume of 1,920,769 shares were traded at the close of the day’s session.

In the last one week, shares of Cymabay Therapeu have slipped by -7.33%.

Cymabay Therapeu's Key Ratios

Cymabay Therapeu has a market cap of $837.64 million, indicating a price to book ratio of 5.7554 and a price to sales ratio of 0.

In the last 12-months Cymabay Therapeu’s revenue was $0 with a gross profit of $-43734000 and an EBITDA of $-92411000. The EBITDA ratio measures Cymabay Therapeu's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cymabay Therapeu’s operating margin was 0% while its return on assets stood at -41.71% with a return of equity of -109.78%.

In Q4, Cymabay Therapeu’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cymabay Therapeu’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cymabay Therapeu’s profitability.

Cymabay Therapeu stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0321. Its price to sales ratio in the trailing 12-months stood at 0.

Cymabay Therapeu stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$141.85 million

Total Liabilities

$15.44 million

Operating Cash Flow

$0

Capital Expenditure

$137000

Dividend Payout Ratio

0%

Cymabay Therapeu ended 2023 with $141.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $141.85 million while shareholder equity stood at $36.15 million.

Cymabay Therapeu ended 2023 with $0 in deferred long-term liabilities, $15.44 million in other current liabilities, 8000.00 in common stock, $-872857000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.29 million and cash and short-term investments were $135.49 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Cymabay Therapeu’s total current assets stands at $138.07 million while long-term investments were $0 and short-term investments were $115.19 million. Its net receivables were $0 compared to accounts payable of $1.10 million and inventory worth $0.

In 2023, Cymabay Therapeu's operating cash flow was $0 while its capital expenditure stood at $137000.

Comparatively, Cymabay Therapeu paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$8.47

52-Week High

$10.05

52-Week Low

$1.67

Analyst Target Price

$12.3

Cymabay Therapeu stock is currently trading at $8.47 per share. It touched a 52-week high of $10.05 and a 52-week low of $10.05. Analysts tracking the stock have a 12-month average target price of $12.3.

Its 50-day moving average was $8.21 and 200-day moving average was $4.8 The short ratio stood at 3.29 indicating a short percent outstanding of 0%.

Around 34% of the company’s stock are held by insiders while 7444.2% are held by institutions.